# An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors

> **NCT06076291** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Hangzhou Sumgen Biotech Co., Ltd.** · enrollment: 122 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** SG1827

## Key facts

- **NCT ID:** NCT06076291
- **Lead sponsor:** Hangzhou Sumgen Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-27
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 122 (ESTIMATED)
- **Last updated:** 2025-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06076291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06076291, "An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06076291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*